Life Biosciences says it just dosed its first patient in an FDA-approved clinical trial to reverse age-related blindness.
The FDA recently approved the cellular rejuvenation therapy ER-100 for human clinical trials. While vision is the first target, it could have applications for a variety of age-related disease.
Add Yahoo as a preferred source to see more of our stories on Google. The Phase 1 study remains deliberately small—under 20 participants across multiple clinical sites. Safety tops the priority list, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results